Media Articles Related to Innopran XL (Propranolol)
Calorie restriction improves sleep apnea, hypertension in obese people
Source: Hypertension News From Medical News Today [2014.09.12]
Restricting calories may improve obstructive sleep apnea and reduce high blood pressure in obese adults, according to a study presented at the American Heart Association's High Blood Pressure...
Hypertension up to Six Times More Likely in Obese vs Slim Youth
Source: theheart.org | Medscape Cardiology Headlines [2014.09.10]
Overweight and obese boys and girls were much more likely to have hypertension than normal-weight children in a new study; thus, weight loss should be encouraged to reduce later CVD risk.
Hypertension is a nearly 6 fold risk factor in obese youths
Source: Hypertension News From Medical News Today [2014.09.03]
Obese youths have a nearly six fold risk of hypertension, according to research in more than 22 000 young people from the PEP Family Heart Study presented at ESC Congress by Professor Peter Schwandt...
Stroke risk increased by resistant hypertension: 35 percent in women and 20 percent in elderly Taiwanese
Source: Hypertension News From Medical News Today [2014.09.03]
Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan.
Potential to treat pulmonary hypertension with protein in 'good cholesterol'
Source: Cholesterol News From Medical News Today [2014.09.01]
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis.
Published Studies Related to Innopran XL (Propranolol)
The study of antiarrhythmic medications in infancy (SAMIS): a multicenter,
randomized controlled trial comparing the efficacy and safety of digoxin versus
propranolol for prophylaxis of supraventricular tachycardia in infants. 
CONCLUSIONS: There was no difference in SVT recurrence in infants treated with
Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. [2011.10]
OBJECTIVES: Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome. Our secondary objective was to describe a randomized, controlled, single-blinded trial comparing propranolol to prednisolone for treatment of IH... CONCLUSIONS: Propranolol is an attractive alternative to other treatments for IH. Despite apparent widespread use of this medication, the data are limited, and prospective studies are lacking for this indication. The relatively high rate of adverse effects supports the need for careful monitoring of patients on this therapy. Fastidious reporting of adverse events and objective evaluation of early and late outcomes are necessary to improve our understanding of the use of propranolol for this indication.
A randomized controlled trial of propranolol for infantile hemangiomas. [2011.08]
OBJECTIVE: Propranolol hydrochloride is a safe and effective medication for treating infantile hemangiomas (IHs), with decreases in IH volume, color, and elevation... CONCLUSION: Propranolol hydrochloride administered orally at 2 mg/kg per day reduced the volume, color, and elevation of focal and segmental IH in infants younger than 6 months and children up to 5 years of age.
Endoscopic variceal band ligation compared with propranolol for prophylaxis of first variceal bleeding. [2011.04]
Administration of nonselective beta-blockers in prophylaxis of first variceal bleeding is not suitable for all patients. Thus, we evaluated endoscopic variceal band ligation (EVBL) in primary prevention of bleeding in patients with cirrhosis and large esophageal varices... In conclusion, EVBL was an effective and safe alternative to propranolol in primary prophylaxis of bleeding in patients with large esophageal varices.
Effect of propranolol on word fluency in autism. [2011.03]
OBJECTIVE AND BACKGROUND: Autism is characterized by repetitive behaviors and impaired socialization and communication. Preliminary evidence showed possible language benefits in autism from the beta-adrenergic antagonist propranolol. Earlier studies in other populations suggested propranolol might benefit performance on tasks involving a search of semantic and associative networks under certain conditions. Therefore, we wished to determine whether this benefit of propranolol includes an effect on semantic fluency in autism... CONCLUSIONS: Results are consistent with a selective beneficial effect of propranolol on flexibility of access to semantic and associative networks in autism, with no observed effect on phonological networks. Further study will be necessary to understand potential clinical implications of this finding.
Clinical Trials Related to Innopran XL (Propranolol)
Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH) [Recruiting]
This is a prospective randomized, double-blind study to compare the clinical efficacy of
infantile hemangioma treatment using propranolol with corticosteroids as compared to therapy
with corticosteroids and placebo. We hypothesize that a two-month treatment period with
propranolol plus corticosteroids is more effective at reducing infantile hemangioma size and
vascularity when compared to corticosteroids used without propranolol for the same time
TRAUMA HELP: Healing and Analgesia With Propranolol [Recruiting]
The purpose of this study is to determine whether propranolol can decrease pain symptoms in
a common subset of patients admitted to a trauma center after injury.
Propranolol Treatment of Traumatic Memories (PTTM) [Recruiting]
This study will compare the responses of subjects with traumatic memories of varying
vintages to either propranolol or placebo in a double-blind setting. It is hypothesized that
those subjects who receive propranolol will experience less emotional distress when the
memory is subsequently reactivated and less spontaneous re-experiences.
Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD) [Recruiting]
Understanding what treatments may facilitate perioperative care of Veterans with
posttraumatic stress disorder (PTSD) is of great importance to the U. S. health care system.
Patients with PTSD are characterized by elevated central nervous system catecholamine
concentrations and exaggerated and prolonged adrenergic responses to stress stimuli. At
present, there are no data on the effects of perioperative beta blocker therapy in patients
with PTSD, despite the rising significance of PTSD in Veteran populations.
This prospective, double-blind study proposes to randomize 150 Veterans with PTSD scheduled
for orthopedic, thoracic or vascular surgery at the San Francisco VA Medical Center to
either a 14-day course of propranolol or placebo. This study will then follow these
Veterans for a one-year period to evaluate the effects of the intervention on Veterans'
The investigators hypothesize that patients with PTSD randomized to the propranolol group
will demonstrate a reduced incidence of perioperative and postoperative morbidity and
Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) [Recruiting]
An open label, prospective, randomized cross-over phase II study in up to 60 sickle cell
patients who are either homozygous for Hb S or have HbSB0 thalassemia. Initially, each
patient will be treated for 6 weeks with placebo or a standard dose of propranolol (40 mg)
every 12 hrs. This will be followed by a 2-week washout period after which, patients will
receive the other treatment modality (placebo or propranolol).
We Hypothesize that propranolol administered in vivo on a daily basis for 6 weeks (1) will
decrease baseline adhesion to endothelial cells and will substantially abrogate
epinephrine-stimulated adhesion to endothelial cells, as measured in vitro; (2) will improve
biomarkers of endothelial activation and dysfunction; and (3) can be safely used in patients
with SCD. Thus, the use of propranolol in SCD may represent a safe and effective means of
anti-adhesive therapy in SCD.
• To establish the safety and efficacy of long-term therapy with propranolol as an
anti-adhesive therapy for SCD.
• To evaluate changes in soluble markers of endothelial activation and dysfunction.
Correlative Science Objective:
• To determine whether response to propranolol therapy is associated with polymorphisms in
genes encoding the proteins involved in the upregulation of SS RBC adhesion by epinephrine.